Novartis Faces Lawsuit Over Alleged 'Sham' Gilenya Promotions
Novartis is accused of organizing 'sham' events to promote Gilenya, resulting in fraudulent claims to government health insurance programs. Discover the details.
Topic
Healthcare
A collection of 81 issues
Court Revives Whistleblower Suit Against Novartis Over Gilenya Kickbacks
U.S. appeals court reinstates lawsuit accusing Novartis of illegal kickbacks to boost sales of its MS drug Gilenya. Explore legal, pharmaceutical, and healthcare implications.
Novartis Hit with Whistleblower Lawsuit Over Gilenya Kickbacks
Novartis is facing legal scrutiny as a whistleblower lawsuit alleges the company paid kickbacks to promote its MS drug Gilenya, impacting the healthcare sector.
Rodman & Renshaw Downgrades Viracta Therapeutics
Rodman & Renshaw downgrade Viracta Therapeutics to Neutral, slashing price target from $3.50 to 25c. Key implications for healthcare and clinical trials.
Breakup Fee Increased to $275M in Healthcare M&A Deal
The breakup fee for a healthcare M&A deal has been raised to $275 million, with possibilities of reaching $325 million under specified conditions.
Amedisys Shares Surge 4.7% in Pre-Market Trading
Amedisys shares see a 4.7% rise in pre-market trading, while UnitedHealth shares remain stable. Explore market reactions in the healthcare sector.
Justice Department Challenges Home-Health Merger Over Antitrust Concerns
The Justice Department raises antitrust issues, challenging a major merger in the home-health and hospice services sector, affecting market competition.
UnitedHealth and Amedisys Extend $3.3 Billion Merger Deadline
UnitedHealth Group and Amedisys have postponed the completion of their $3.3 billion merger, focusing on regulatory approvals in the healthcare industry.
UnitedHealth and Amedisys Extend $3.3B Merger Deadline Amid Antitrust Hurdles
UnitedHealth and Amedisys have pushed back the deadline for their $3.3 billion merger as they grapple with antitrust challenges from the DOJ. Discover the latest updates in healthcare M&A.
UnitedHealth and Amedisys Extend $3.3B Merger Deadline
UnitedHealth Group and Amedisys have extended their $3.3 billion merger deadline to next year, impacting healthcare mergers and acquisitions momentum.